Kalaris Therapeutics, Inc. Common Stock KLRS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $32.3M+5.0% | $30.75M+12.0% | $27.45M-49.5% | $54.34M+10.6% | $49.11M+9.0% | ||
| $15.34M-0.4% | $15.4M+2.4% | $15.04M+13.5% | $13.25M+27.3% | $10.41M+55.6% | ||
| $47.63M+3.2% | $46.15M+8.6% | $42.48M-37.1% | $67.59M+13.6% | $59.52M+15.1% | ||
| -$47.63M-3.2% | -$46.15M-8.6% | -$42.48M+37.1% | -$67.59M-13.6% | -$59.52M-15.1% | ||
| $0-100% | $1.44M-47.6% | $2.75M-22.8% | $3.57M-12.3% | $4.07M+50.5% | ||
| $3.53M+30.2% | $2.71M+121% | -$12.98M+7.7% | -$14.06M+14.4% | -$16.43M+5.7% | ||
| -$44.1M-1.5% | -$43.44M+21.7% | -$55.47M+32.1% | -$81.66M-7.5% | -$75.96M-9.8% | ||
| -$2.15+48.9% | -$4.21+79.1% | -$20.10+57.8% | -$47.62+7.1% | -$51.27+0.2% | ||
| -$47.63M-3.2% | -$46.15M-8.6% | -$42.48M+37.1% | -$67.59M-13.6% | -$59.52M-15.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Kalaris Therapeutics, Inc. Common Stock profitable?
- Kalaris Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $44.1M over the trailing twelve months.
- What is Kalaris Therapeutics, Inc. Common Stock's earnings per share?
- Kalaris Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-2.15.
- Where does Kalaris Therapeutics, Inc. Common Stock's income statement data come from?
- Every line is extracted from Kalaris Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.